Aster DM Healthcare Ltd. share price target

increased sharply over the last 3 years (29% CAGR over FY22-25). Our FY2627E EBITDA estimate broadly unchanged. We estimate 24% EBITDA CAGR over FY25-27E aided by scale-up in margins, healthy ARPOB and bed additions. ASTER DM's board has recently approved merger with Quality care (QCIL) that...

Aster DM Healthcare’s (Aster) Q3FY23 performance exceeded our expectations on revenue front, largely driven by strong growth in GCC hospitals and pharmacies. Consolidated revenue grew 20.5% YoY to Rs31.9bn (I-Sec: Rs28.1bn). GCC hospitals posted healthy growth of 22% YoY.

Aster DM Healthcare’s (Aster) Q2FY23 performance was below our estimates on the
profitability front. This was mainly due to depressed margins in the GCC clinics business and losses incurred by the newly commissioned GCC hospitals.

Aster DM Healthcare’s (Aster) Q1FY23 performance was below our estimates on profitability front.

Revenue break-up 9MFY22: hospitals: 56%, pharmacies: 21%, clinics: 23% with GCC & India contributing 76% & 24% of revenues, respectively Q3FY22 Results: Good numbers driven by significant improvement in footfalls...

...

...

Strong RoCE in GCC despite aggressive expansion Aster derives ~81% of revenues from GCC countries. In the last six years, it expanded its hospitals, clinics, pharmacy count by ~2x. However, despite aggressive expansion, RoCE stayed healthy [hospitals- 12% (established hospitals- 25%), clinics- 21% and pharmacies- 44%] due to 1) asset light model, 2) integrated business model, 3) faster occupancy owing to strong brand equity, 4) healthy ARPOB and 5) targeted strategy. We believe RoCE would improve further due to continuing improvement in occupancy,...

Q4FY20 revenues grew 4.6% YoY to | 2301 crore. EBITDA margins expanded 163 bps YoY to 17.6% mainly due to lower other expenses on Ind-AS adjustment. Subsequent EBITDA grew 15.3% YoY to | 404 crore. However, PAT fell 37.4% YoY to | 131 crore. Delta vis-a-vis EBITDA was mainly due to higher interest & depreciation expenses due to Ind-AS 116....

Strong RoCE in GCC despite aggressive expansion Aster derives ~81% of revenues from GCC countries. In the last six years, the company has expanded its hospitals, clinics and pharmacy count by almost 2x. However, despite aggressive expansion, the RoCE has remained healthy (hospitals- 13% (established hospitals - 27%), clinics - 25% and pharmacies - 45%) due to 1) asset light model, 2) integrated business model, 3) faster occupancy owing to strong brand equity, 4) healthy ARPOB and 5) targeted strategy. We believe RoCE will improve further due to continuing...

Aster DM Healthcare Ltd. (Aster) is one of the largest private healthcare service providers, having operations in multiple GCC (Cooperation Council for the Arab States of the Gulf) states based on numbers of hospitals and clinics. The issue is a combination of fresh and OFS. The company will not receive any proceeds from the OFS. Net proceeds from the fresh issue would be around Rs. 6,750mn. Of the net proceeds, around Rs. 5,641.6mn, would be utilized to prepay and/or repayment of the...